Triple negative breast cancer (TNBC) constitutes approximately 20% of breast cancers and is defined by lack of expression of the estrogen receptor (ER) and progesterone (PR) receptors and lack of overexpression of human epidermal growth factor receptor 2 (HER2) 1,2. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.